5.2% CAGR by 2032 forecast for heart failure market

17 October 2023

With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from $31.9 billion in 2022 to $53 billion in 2032 across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, UK and Japan), forecasts and analytics company GlobalData.

Kajal Jaddoo, senior analyst at GlobalData, comments: “The pressure for pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the HF market with the strategies of optimizing treatment safety and compliance, as well as developing novel drug classes. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has remained relatively consistent, and the use of sodium-glucose transporter 2 inhibitors has become well established for HF.”

Recent and upcoming product launches

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK